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PCRs were performed with primers
from the internal regions of bla CTX-M
gene and primers for insertion
sequences ISEcp1 and IS903 (4,5).
Positive PCR products were obtained
with primers ISEcp1F and CTX2 (943
bp); no amplified product was pro-
duced with primers CTX1 and
IS903R. Sequencing of a 943-bp
amplicon showed that blaCTX-M15 was
flanked upstream by an ISEcp1-like
element. 
The presence of an integron in S.
sonnei WA7593 and WA7593TC1
was investigated by using integron-
specific primers hep35 and hep36 (2).
Only S. sonnei WA7593 produced a
PCR product. This finding suggests
that the transmission of blaCTX-M15 is
not by integron-mediated transfer. A
further 162 Shigella spp. and 260
Salmonella spp. isolated from 2003
through 2005 were also screened for
ESBL production; no further isolates
were identified. 
The presence of a CTX-M–type,
ESBL-producing isolate is rarely
reported in the United States. The
only other reference was from a mul-
tistate study in 2001–2002 that identi-
fied CTX-M type from E. coli isolates
from urine, sputum, and blood (6). No
further reports about CTX-M–produc-
ing organisms have been disseminat-
ed. Our investigation suggests that
CTX-M–type ESBLs may spread
throughout the United States through
infected travelers. This finding is
notable because S. sonnei is a com-
mon enteric pathogen. Our results fur-
ther emphasize that travelers from
others parts of the world can introduce
highly mobile and clinically impor-
tant resistance mechanisms into the
community. The spread of CTX-M
ESBLs may be faster and more wide-
spread than previously thought; there-
fore, CTX-M type should be taken
seriously as a surveillance target in
the United States, especially in
patients with a history of travel out-
side North America.
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HIV and Hepatitis C
Virus Coinfection,
Cameroon
To the Editor: Coinfection with
HIV and hepatitis C virus (HCV) is
now a major public health concern
worldwide, owing both to its high
prevalence (4–5 million persons of 40
million infected by HIV) and to inter-
actions between the 2 diseases in
terms of their diagnosis, natural
course, and treatment (1,2). Although
Africa is the continent by far the most
badly affected by both HIV and HCV
infections, data on coinfection in the
general population are lacking. In
Cameroon, a central African country,
the HCV seroprevalence is among the
highest in the world (13.8%) (3). We
have also reported a high seropreva-
lence of HIV in a general population
of southern Cameroon (7.4%), and
especially in young women (22.5%)
(4). Here, we investigated the preva-
lence of HIV/HCV coinfection in this
population.
A population-based, cross-sec-
tional survey was conducted in
September 2001 in 3 villages of the
East Province of Cameroon (250 km
from Yaoundé, the capital city). The
study methods, the baseline character-
istics of the participants, and the HIVLETTERS
seroprevalence have been described
in detail elsewhere (4). Briefly, all
inhabitants >15 years of age were eli-
gible for the survey. After giving their
informed consent, the participants
were interviewed by using a standard
verbal questionnaire, in French or in a
local language, during door-to-door
visits. Blood samples were collected
by peripheral venipuncture, and
serum was screened for antibodies to
HCV by using an enzyme immunoas-
say (INNOTEST HCV Ab IV,
Innogenetics, Ghent, Belgium).
Samples with indeterminate results
were retested. All positive and twice-
indeterminate samples were con-
firmed with a third-generation line
immunoassay (INNO-LIA HCV Ab
III update, Innogenetics). Serologic
screening for HIVinfection was based
on an enzyme immunoassay (Murex
HIV-1.2.O, Abbott, Rungis, France).
All positive samples were confirmed
by using a line immunoassay (INNO-
LIA HIV-1+2, Innogenetics).
Among the 484 participants, 256
were women (52.9%), and the median
age was 34 years (interquartile range
23–52 years). Most participants
(93.6%) were Bantus; the remainder
were pygmies. Seven persons refused
venipuncture after the interview, and 1
sample could not be analyzed. These 8
persons did not differ from the rest of
the study population in term of sex
(50.0% women vs. 47.1% women),
but they were slightly younger (medi-
an, 26.8 years vs. 34.9 years). Of the
476 available samples, respectively 19
(4.0%) had indeterminate HCV sero-
logic results, and 5 (1.1%) had indeter-
minate HIV serologic results. The
overall seroprevalence rates were
21.0% (95% confidence interval [CI]
17.4%–24.9%) for HCV and 7.4%
(95% CI 5.2%–10.1%) for HIV. Only
3 patients (0.6%) had positive results
for both infections: a man 29 years of
age and 2 women ages 36 and 52
years.
The Figure shows the seropreva-
lence rates of HCV and HIV accord-
ing to sex and age. Multivariate ran-
dom-effects logistic regression analy-
ses showed different risk factors for
the 2 infections. The HCV seropreva-
lence was associated with age (<45
vs. >45 years, odds ratio [OR] 13.04;
95% CI 6.73–25.30; p<0.001), sex
(men vs. women, OR 2.02; 95% CI
1.17–3.47; p = 0.01) and the ethnic
group (Bantus vs. pygmies, OR 10.98;
95% CI 1.31–92.42; p = 0.03). In con-
trast, the HIV seroprevalence was
higher in women than in men (OR
10.22; 95% CI 3.19–32.80; p<0.001).
No specific risk factors were found in
men, whereas women who were
unmarried (OR 6.49; CI 2.45–17.17;
p<0.001) or school-educated (OR
7.12; 95% CI 1.59–31.78; p = 0.01),
or those with a history of sexually
transmitted infections (OR 2.92; 95%
CI 1.08–7.89; p = 0.03) had higher
rates than other women.
HIV/HCV coinfection is there-
fore rare in this general population,
which lives in an area where both
HCV and HIV are endemic. This find-
ing could be related to the dissimilar
epidemiologic patterns of the 2 infec-
tions. Indeed, HIV infection mainly
affects young persons, especially
young women, while HCV infection
is more frequent in older persons of
both sexes. We have previously postu-
lated that HIV is likely to be transmit-
ted by the sexual route, in a context of
commercial logging and the extensive
and complex sexual networks it
induces (4). In contrast, the route of
HCV transmission is unclear. HCV
seropositivity was not associated with
a history of blood transfusion, injec-
tions, surgery, scarification, or tattoo-
ing. Intravenous drug use was not
investigated in our study but was like-
ly to be infrequent. Although sexual
transmission could not be ruled out,
especially between regular partners,
the shape of the seroprevalence
curves and the lack of association
with HIV infection, syphilis, or other
sexually transmitted infections sug-
gests that this mode of transmission is
inefficient, in keeping with other
reports (5,6). Our seroprevalence
curves and the study location are con-
sistent with the hypothesis that fre-
quent iatrogenic transmission
occurred during mass medical cam-
paigns conducted before 1960 (7).
The rate of HCV coinfection among
the HIV-infected subjects in our study
(8.6%) is much lower than the overall
rate (25%–30%) in North America
and Europe (1,2), where intravenous
drug use is a major risk factor for both
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infections (8,9). This rate was even in
the lower range of values found
among HIV-infected heterosexual
persons in industrialized countries
(9%–27%) (2). Our results therefore
suggest that the high seroprevalence
rates of HIV and HCV in Africa will
not necessarily result in a high preva-
lence of HIV/HCV coinfection.
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Republic of Korea 
To the Editor: Amebic liver
abscess (ALA) is the most common
extraintestinal complication of ame-
bic infection. Although loss of cellular
immunity is thought to play a role in
infection by the pathogen, whether
HIV infection is also a risk factor for
invasive amebiasis is controversial
(1–3). ALA in HIV-infected patients
has not been well characterized,
although several case series have been
reported (2,4). We report the role of
HIVinfection status in ALAin an area
where ALA is not endemic and the
clinical features of ALA in HIV-
infected patients.
All patients with ALA at Seoul
National University Hospital (SNUH)
from January 1990 through December
2005 were identified; some have been
previously reported (5). SNUH is a
1,600-bed, university-affiliated teach-
ing hospital and the largest referral
center for HIV/AIDS in the Republic
of Korea. The diagnostic criteria for
ALA were radiologic evidence of
intrahepatic abscess, trophozoites of
Entamoeba histolytica in fluid aspi-
rated from an abscess, or absence of
bacteria and fungi in aspirated
fluid and a titer ≥128 in an indirect
hemagglutination assay (IHA) for
E. histolytica.
Of 31 patients with ALA at
SNUH from 1990 through 2005, 10
(32%) were HIVpositive. The propor-
tion of HIV-infected patients among
patients with ALA increased signifi-
cantly with time (linear-by-linear
association, p<0.001) (Figure). Of 10
patients from 1998 through 2005, 8
(80%) were HIV positive. Except for
2 patients with a history of travel to an
ALA-endemic area, 88% of the
patients were HIV positive.
Median age of the 10 HIV-posi-
tive patients with ALAwas 34.5 years
(range 29–54 years); all patients were
male. Four had a homosexual orienta-
tion, 4 had a heterosexual orientation,
and 2 had an unknown sexual orienta-
tion. Fever (100%) was the most com-
mon symptom, and abdominal tender-
ness (90%) and diarrhea (50%) were
frequently observed. Median leuko-
cyte count was 9,000/mm3 (range
3,410–16,700/mm3), and median CD4
cell count was 279/mm3 (range
40–370/mm3). Eight patients had
abscesses in the right lobe of the liver
and 2 had abscesses in both lobes; 8
patients had 1 abscess and 2 had mul-
tiple abscesses. Median size of
abscesses was 7.25 cm (range 3–12
cm). In 5 patients, pleural effusion
was observed in chest radiographs.
IHA titer was >128 in 10 patients and
>512 in 8 patients. Median days to
defervescence was 2 (range 1–5
days). In 2 patients, perforation of the
abscess into the abdominal cavity was
a complication. No patients died or
had relapses.
Early in the AIDS pandemic,
some studies reported that the preva-
lence of invasive amebiasis was not
increased in patients with HIV infec-
tion (1,6). However, recent reports of
ALA associated with HIV infection
have increased. Studies in Taiwan
demonstrated that invasive amebiasis,
including ALA, is on the increase in
HIV-infected patients in disease-
endemic areas (2,7).